New Acne Therapies and Updates on Use of Spironolactone and Isotretinoin: A Narrative Review
| Autor: | Jane J. Han, Arash Mostaghimi, Adam Faletsky, John S. Barbieri |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Dermatology Review Spironolactone 030207 dermatology & venereal diseases 03 medical and health sciences chemistry.chemical_compound Retinoids 0302 clinical medicine Tazarotene Tretinoin medicine Intensive care medicine Isotretinoin Acne Sarecycline business.industry Clascoterone medicine.disease Clinical trial chemistry Tolerability 030220 oncology & carcinogenesis business medicine.drug |
| Zdroj: | Dermatology and Therapy |
| ISSN: | 2190-9172 2193-8210 |
| Popis: | Acne vulgaris is a chronic inflammatory skin disease with a multifactorial pathogenesis. Although a variety of acne treatments are available, limitations of current therapies include tolerability, antimicrobial resistance, and costs and patient burden associated with monitoring. This narrative review focuses on emerging treatments and updates on the management of acne. Clascoterone, sarecycline, trifarotene, and novel lotion formulations of tretinoin and tazarotene have been evaluated in clinical trials and provide new options for treatment. Emerging data on the safety and efficacy of spironolactone and isotretinoin challenge current conventions and suggest a need to reconsider drug monitoring guidelines and risk prevention systems. Additional head-to-head data are needed to confirm these novel treatments' utility in treating acne. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink